[go: up one dir, main page]

WO2004022032A2 - Forme posologique pharmaceutique comprenant un compose de sulfite - Google Patents

Forme posologique pharmaceutique comprenant un compose de sulfite Download PDF

Info

Publication number
WO2004022032A2
WO2004022032A2 PCT/US2003/024044 US0324044W WO2004022032A2 WO 2004022032 A2 WO2004022032 A2 WO 2004022032A2 US 0324044 W US0324044 W US 0324044W WO 2004022032 A2 WO2004022032 A2 WO 2004022032A2
Authority
WO
WIPO (PCT)
Prior art keywords
dosage form
ethers
fill material
glycol
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/024044
Other languages
English (en)
Other versions
WO2004022032A3 (fr
Inventor
Ping Gao
Juliane M. Bauer
Gary Ewing
David Sperry
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Priority to BR0313064-9A priority Critical patent/BR0313064A/pt
Priority to CA002493974A priority patent/CA2493974A1/fr
Priority to MXPA05001272A priority patent/MXPA05001272A/es
Priority to AU2003257102A priority patent/AU2003257102A1/en
Priority to JP2004534259A priority patent/JP2006500389A/ja
Priority to EP03794452A priority patent/EP1526847A2/fr
Publication of WO2004022032A2 publication Critical patent/WO2004022032A2/fr
Publication of WO2004022032A3 publication Critical patent/WO2004022032A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Definitions

  • the present invention relates to gelatin capsules filled with a fill material comprising a selective COX-2 inhibitory drug of low water solubility and a sulfite compound and to reduced gelatin cross-linking thereof.
  • Gelatin a mixture of water-soluble proteins derived from collagen by hydrolysis, is widely used in the pharmaceutical and food industries, among others.
  • One major application of gelatin is in preparation of both hard and soft gelatin capsules.
  • Such capsules are desirable for, ter alia, their versatility (they may contain drug formulations in solid, semi-solid, or liquid form) and for their rapid dissolution characteristics.
  • drug dosage forms containing gelatin in an outer layer e.g. liquid or powder filled into a gelatin capsule
  • a pharmaceutical dosage form comprising a fill material in a gelatin capsule could be prepared which are capable of providing a predictable and stable drug dissolution rate, even after storage under stressed conditions, a significant advance in the oral delivery of drugs, particularly drugs of low water solubility or drugs whose absorption is dissolution-rate limited, would result.
  • a pharmaceutical dosage form comprising a fill material sealed in a gelatin capsule shell, the fill material comprising (a) a selective COX-2 inhibitory drug of low water solubility, and (b) a sulfite compound, in an amount sufficient to inhibit cross-linking and/or pellicle formation of the gelatin capsule shell upon storage.
  • the sulfite compound in the dosage form is present at a concentration sufficient to (a) inhibit cross-linking of the gelatin and/or pellicle formation in the capsule shell and/or (b) provide a dosage form with a stable dissolution profile.
  • the dosage form of the present invention is especially useful for liquid fill materials and for soft gelatin capsules.
  • pellicle refers to a relatively water-insoluble membrane formed in a gelatin capsule shell. Such a membrane tends to be thin, tough, and rubbery. It is now understood that one mechanism underlying pellicle formation is gelatin cross- linking. Gelatin cross-linking and pellicle formation result in reduced dissolution rates. Accordingly, quantification of dissolution rate of a first capsule within a reasonably short time after capsule preparation and of a second capsule after storage under stressed conditions (e.g., four weeks at 40°C and 85% relative humidity in a closed container) as described herein provides one means of assessing pellicle formation and/or gelatin cross- linking.
  • the term "within a reasonably short time after capsule formation” means within a period such that substantial cross-linking and/or pellicle formation is unlikely to have yet occurred, for example within one week, dependent upon storage conditions during that period.
  • pellicle-resistant herein means that a gelatin capsule so described has a reduced tendency to form, or exhibits slowed, delayed or reduced formation of a pellicle upon storage under stressed conditions.
  • inhibitor of cross-linking herein means a slowed, delayed or reduced formation of gelatin cross-links (or pellicle formation) in a capsule by comparison with an otherwise similar capsule lacking only the amine agent as provided herein.
  • Pharmaceutical dosage forms according to the present invention have been found to exhibit an unexpected and surprisingly substantial reduction in cross-linking of gelatin in the gelatin capsule shell and reduction in pellicle formation. As a result, such dosage forms are capable of consistently meeting desired in vitro dissolution criteria, even after storage under stressed conditions. This invention represents a significant improvement over conventional dosage forms.
  • Figure 1 is a graph showing Tier I dissolution rate of Formulation 30 following storage at 25° C as described in Example 3.
  • FIG. 1 is a graph showing Tier I dissolution rate of Formulation 30 following storage at 40° C as described in Example 3.
  • Figure 3 is a graph showing Tier II dissolution rate of Formulation 30 following storage at 25° C as described in Example 3.
  • FIG. 4 is a graph showing Tier II dissolution rate of Formulation 30 following storage at 40° C as described in Example 3.
  • FIG. 5 is a graph showing Tier I dissolution rate of Formulation 19 following storage at 25° C as described in Example 3.
  • FIG. 6 is a graph showing Tier I dissolution rate of Formulation 19 following storage at 40° C as described in Example 3.
  • Figure 7 is a graph showing Tier II dissolution rate of Formulation 19 following storage at 40° C as described in Example 3.
  • the present invention provides a dosage form comprising a fill material sealed in a gelatin capsule shell, the fill material comprising (a) a selective cyclooxygenase-2 inhibitory drug of low water solubility and (b) at least one pharmaceutically acceptable sulfite compound in an amount sufficient to inhibit cross- linking and/or pellicle formation in the gelatin capsule shell upon storage.
  • Gelatin cross-linking can result from a process by which amino acid residues of gelatin covalently bond to form an insoluble material. The process can be the result of low levels of aldehydes coming into contact with the gelatin.
  • Cross-linking of a gelatin capsule can impact product performance by delaying the release of the formulation (containing the active compound) from the capsule shell. The delay in release can, in turn, affect the rate of absorption of the compound into the blood stream and clinical onset of action.
  • Dosage forms of the present invention exhibit decreased gelatin cross-linking (and pellicle formation) and, therefore, when placed in an in vitro dissolution assay, are capable of advantageously exhibiting less dissolution rate change during storage under stressed conditions than conventional dosage forms. Dosage forms according to the present invention also exhibit more uniform inter-dosage form drug dissolution rate than standard dosage forms.
  • the fill material further comprises at least one substance that promotes cross-linking of gelatin when in contact therewith (the substance being the drug itself or an excipient substance, and the substance acting independently or in combination with one or more other substances to promote said cross-linking); upon (a) immediately testing a first dosage form in a first in vitro dissolution assay; (b) storing a second dosage form which is identical to the first dosage form in a closed container maintained at 40 °C and 75% relative humidity for a period of four weeks and, after said storage; (c) testing the second dosage form in a second in vitro dissolution assay which is identical to the first in vitro dissolution assay; the amount of drug dissolved at 45 minutes in the second dissolution assay is within ⁇ 15 percent and preferably within ⁇ 10 percent of the amount of drug dissolved at 45 minutes in the first dissolution assay.
  • the substance being the drug itself or an excipient substance, and the substance acting independently or in combination with one or more other substances to promote said cross-linking
  • a dosage form is placed in a USP apparatus II with a rotating paddle with a paddle speed of 50 rpm in 900 mL of 0.01N HCl + 1% Tween 80. Samples are typically withdrawn at 15, 30, 45, 60 and 90 minutes and assayed for drug content by HPLC.
  • the Tier II test employs the addition of the enzyme pepsin to the medium.
  • Pepsin in the human stomach digests cross-linked gelatin.
  • the appropriate amount of pepsin added to the media (750,000 units/L) was determined and reported in Collaborative Development of Two-Tier Dissolution Testing for Gelatin Capsules and Gelatin-Coated Tablets using Enzyme-Containing Media, Stimuli to the Revision Process, Pharmacopeial Forum, Vol. 25, No. 5, Sept.-Oct. 1998.
  • the Tier ⁇ drug release test designed in this way is expected to produce a drug release profile that is a reasonable approximation of the drug release profile in humans.
  • An 'initial' drug release profile is determined for each dosage form within a reasonably short time after preparation (i.e. before the dosage form is exposed to conditions that might result in gelatin cross-linking, such as temperature or relative humidity).
  • a subsequent profile is determined for samples pulled at subsequent time points.
  • a change from initial to subsequent Tier I profile i.e. a delay in dissolution
  • Dosage forms of the invention comprise a selective cyclooxygenase-2 inhibitory drug, also referred to herein as a selective COX-2 inhibitory drug.
  • the COX-2 inhibitory drug is a drug of low water solubility (e.g. having a room temperature solubility in water of not more than about 10 mg/ml and more preferably not more than about 1 mg/ml).
  • a preferred selective COX-2 inhibitory drug useful herein, or to which a salt or prodrug useful herein is converted in vivo, is a compound of formula (I)
  • A is a substituent selected from partially unsaturated or unsaturated heterocyclyl and partially unsaturated or unsaturated carbocyclic rings, preferably a heterocyclyl group selected from pyrazolyl, furanonyl, isoxazolyl, pyridinyl, cyclopentenonyl and pyridazinonyl groups;
  • X is O, S or CH 2 ; n is 0 or 1;
  • R 1 is at least one substituent selected from heterocyclyl, cycloalkyl, cycloalkenyl and aryl, and is optionally substituted at a substitutable position with one or more radicals selected from alkyl, haloalkyl, cyano, carboxyl, alkoxycarbonyl, hydroxyl, hydroxyalkyl, haloalkoxy, amino, alkylamino, arylamino, nitro, alkoxyalkyl, alkylsulfinyl, halo, alkoxy and alkylthio;
  • R 2 is methyl, amino or aminocarbonylalkyl
  • R 3 is one or more radicals selected from hydrido, halo, alkyl, alkenyl, alkynyl, oxo, cyano, carboxyl, cyanoalkyl, heterocyclyloxy, alkyloxy, alkylthio, alkylcarbonyl, cycloalkyl, aryl, haloalkyl, heterocyclyl, cycloalkenyl, aralkyl, heterocyclylalkyl, acyl, alkylthioalkyl, hydroxyalkyl, alkoxycarbonyl, arylcarbonyl, aralkylcarbonyl, aralkenyl, alkoxyalkyl, arylthioalkyl, aryloxyalkyl, aralkylthioalkyl, aralkoxyalkyl, alkoxyaralkoxyalkyl, alkoxycarbonylalkyl, aminocarbonyl, aminocarbonylalkyl, alkyla
  • R 4 is selected from hydrido and halo.
  • R D is a methyl or amino group
  • R° is hydrogen or a C ⁇ - alkyl or alkoxy group
  • X' is N or CR 7 where R 7 is hydrogen or halogen
  • Y and Z are independently carbon or nitrogen atoms defining adjacent atoms of a five- to six-membered ring that is optionally substituted at one or more positions with oxo, halo, methyl or halomethyl groups, or an isomer, tautomer, pharmaceutically-acceptable salt or prodrug thereof.
  • Preferred such five- to six-membered rings are cyclopentenone, furanone, methylpyrazole, isoxazole and pyridine rings substituted at no more than one position.
  • dosage forms of the invention are suitable for celecoxib, deracoxib, valdecoxib, rofecoxib, etoricoxib, 2-(3,5-difluorophenyl)-3-[4- (methylsulfonyl)phenyl]-2-cyclopenten-l-one, 2-(3,4-difluorophenyl)-4-(3-hydroxy-3- methyl-l-butoxy)-5-[4-(methylsulfonyl)phenyl]-3-(2H)-pyridazinone, pharmaceutically acceptable salts and prodrugs thereof.
  • a particularly useful prodrug of valdecoxib for use in dosage forms of the invention is parecoxib, more particularly parecoxib sodium.
  • Dosage forms of the invention are also useful for compounds having the formula (m):
  • R 8 is lower haloalkyl
  • R 9 is hydrogen or halogen
  • R 10 is hydrogen, halogen, lower alkyl, lower alkoxy or haloalkoxy, lower aralkylcarbonyl, lower dialkylaminosulfonyl, lower alkylaminosulfonyl, lower aralkylaminosulfonyl, lower heteroaralkylaminosulfonyl, or 5- or 6-membered nitrogen-containing heterocyclosulfonyl
  • R 11 and R 12 are independently hydrogen, halogen, lower alkyl, lower alkoxy, or aryl; and for pharmaceutically acceptable salts thereof.
  • An especially useful compound of formula (Dl) is (S)-6,8-dichloro-2- (trifluoromethyl)-2H-l-benzopyran-3-carboxylic acid, particularly in the form of a water- soluble salt thereof, for example the sodium salt.
  • the dosage form typically comprises celecoxib in a therapeutically and/or prophylactically effective total amount of about 10 mg to about 1000 mg per dose unit.
  • the drug is a selective COX-2 inhibitory drug other than celecoxib
  • the amount of the drug per dose unit is therapeutically equivalent to about 10 mg to about 1000 mg of celecoxib.
  • a therapeutically and/or prophylactically effective amount of a drug for a subject is dependent inter alia on the body weight of the subject.
  • a "subject" herein to which a therapeutic agent or composition thereof can be administered includes a human patient of either sex and of any age, and also includes any nonhuman animal, particularly a domestic or companion animal, illustratively a cat, dog or horse.
  • an amount of celecoxib relatively low in the preferred range of about 10 mg to about 1000 mg is likely to be consistent with therapeutic effectiveness.
  • an adult human or a large animal e.g., a horse
  • therapeutic effectiveness is likely to require dose units containing a relatively greater amount of celecoxib.
  • a therapeutically effective amount of celecoxib per dose unit in a dosage form of the present invention is typically about 10 mg to about 400 mg.
  • Especially preferred amounts of celecoxib per dose unit are about 100 mg to about 200 mg, for example about 100 mg or about 200 mg.
  • an amount of the drug per dose unit can be in a range known to be therapeutically effective for such drugs.
  • the amount per dose unit is in a range providing therapeutic equivalence to celecoxib in the dose ranges indicated immediately above.
  • Sulfite compound [0027]
  • Dosage forms of the invention comprise at least one pharmaceutically acceptable sulfite compound.
  • Illustrative pharmaceutically acceptable sulfite compounds include sodium metabisulfite, sodium bisulfite, and sodium thiosulfate (sodium hyposulfite).
  • One or more sulfite compounds are present in a composition of the invention in an amount of not more than about 10%, for example about 0.01% to about 10%, preferably about 0.1% to about 5%, and more preferably about 0.1% to about 2% of the dosage form on a dry weight basis. It should be understood that “on a dry weight basis” means total weight excepting water weight. Similar meaning is conferred by the term “by weight” unless context indicates otherwise.
  • the sulfite compound can additionally, if desired, be present in the gelatin capsule shell.
  • Fill material of the present invention optionally further comprises an amine agent comprising at least one pharmaceutically acceptable primary or secondary amine compound.
  • Any pharmaceutically acceptable primary or secondary amine compound can, if desired, be used in a dosage form of the invention.
  • the term primary or secondary amine compound herein includes those primary and secondary amines which are pharmaceutically acceptable excipients.
  • amine agents of the present invention are compounds that are not therapeutically or nutritionally active.
  • Non-limiting examples of suitable primary amine compounds include tromethamine (Tris), ethanolamine, ethylenediamine, diethylamine, ethylene N-methyl-D-glucamine, and amino acids such as L-arginine, L-lysine, and guanidine.
  • suitable secondary amine compounds include diethanolamine, benethamine (i.e., N- phenymethyl)benezeneethanamine), benzathine (i.e., N,N-dibenzylethylenediamine), piperazine, hydrabamine (i.e., N,N-bis(dehydroabietyl)ethylenediamine), and imidazole.
  • the primary or secondary amine compound is present in a dosage form of the invention in a total amount of not more than about 10%, preferably not more than about 7%, and more preferably not more than about 5% of the dosage form on a dry weight basis, for example about 0.1% to about 4%. In one embodiment, at least about 50%, preferably at least about 55%, more preferably at least about 60%, and still more preferably at least about 65% of any primary or secondary amine compound present in a dosage form of the invention is present in the fill material. iii.
  • Other excipients [0030]
  • a fill material according to the invention can comprise any additional pharmaceutically acceptable excipients.
  • excipients can include, by way of illustration and not limitation, diluents, disintegrants, dispersants, binding agents, adhesives, wetting agents, lubricants, glidants, crystallization inhibitors, stabilizers, antioxidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, preservatives, and substances added to improve appearance of the dosage form.
  • Such optional additional components should be physically and chemically compatible with the other ingredients of the fill material and should not be deleterious to the recipient. Importantly, some of the above-listed classes of excipients overlap each other.
  • Fill material of the present invention optionally further comprises at least one pharmaceutically acceptable free radical-scavenging antioxidant.
  • a free radical- scavenging antioxidant is to be contrasted with a "non-free radical-scavenging antioxidant", i.e., an antioxidant that does not possess free radical-scavenging properties.
  • Non-limiting illustrative examples of suitable free radical-scavenging antioxidants include ⁇ -tocopherol (vitamin E), ascorbic acid (vitamin C) and salts thereof including sodium ascorbate and ascorbic acid palmitate, butylated hydroxyanisole (BHA), butylated hydroxytoluene (BHT), fumaric acid and salts thereof, hypophosphorous acid, malic acid, alkyl gallates, for example propyl gallate, octyl gallate and lauryl gallate, sodium sulfite, sodium bisulfite and sodium metabisulfite.
  • Preferred free radical-scavenging antioxidants are alkyl gallates, vitamin E, BHA and BHT. More preferably the at least one free radical-scavenging antioxidant is propyl gallate.
  • One or more free radical-scavenging antioxidants are optionally present in dosage forms of the invention in a total amount effective to substantially reduce formation of an addition compound, typically in a total amount of about 0.01% to about 5%, preferably about 0.01% to about 2.5%, and more preferably about 0.01% to about 1% of the dosage form on a dry weight basis.
  • Fill material according to the invention optionally comprises one or more pharmaceutically acceptable sweeteners.
  • suitable sweeteners include mannitol, propylene glycol, sodium saccharin, acesulfame K, neotame and aspartame.
  • a viscous sweetener such as sorbitol solution, syrup (sucrose solution) or high-fructose corn syrup can be used and, in addition to sweetening effects, can also be useful to increase viscosity and to retard sedimentation.
  • Fill material of the invention optionally comprises one or more pharmaceutically acceptable preservatives other than free radical-scavenging antioxidants.
  • Non-limiting examples of suitable preservatives include benzalkonium chloride, benzethonium chloride, benzyl alcohol, chlorobutanol, phenol, phenylethyl alcohol, phenylmercuric nitrate, thimerosal, etc.
  • Fill material of the invention optionally comprises one or more pharmaceutically acceptable wetting agents.
  • Surfactants, hydrophilic polymers and certain clays can be useful as wetting agents to aid in dissolution and/or dispersion of a hydrophobic drug such as celecoxib.
  • Non-limiting examples of suitable surfactants include benzalkonium chloride, benzethonium chloride, cetylpyridinium chloride, dioctyl sodium sulfosuccinate, nonoxynol 9, nonoxynol 10, octoxynol 9, poloxamers, polyoxyethylene (8) caprylic/capric mono- and diglycerides (e.g., LabrasolTM of Gattefosse), polyoxyethylene (35) castor oil, polyoxyethylene (20) cetostearyl ether, polyoxyethylene (40) hydrogenated castor oil, polyoxyethylene (10) oleyl ether, polyoxyethylene (40) stearate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80 (e.g., TweenTM 80 of ICI), propylene glycol laurate (e.g., LauroglycolTM of Gattefosse), sodium lauryl sulfate, sorbitan monolaurate, sorbitan monoole
  • dosage forms of the invention optionally comprise one or more pharmaceutically acceptable buffering agents, flavoring agents, colorants, stabilizers and/or thickeners.
  • Buffers can be used to control pH of a formulation and can thereby modulate drug solubility.
  • Flavoring agents can enhance patient compliance by making the dosage form more palatable, and colorants can provide a product with a more aesthetic and/or distinctive appearance.
  • suitable colorants include D&C Red No. 33, FD&C Red No. 3, FD&C Red No. 40, D&C Yellow No. 10, and C Yellow No. 6.
  • fill material comprising the selective COX-2 inhibitory drug is in the form of a liquid. More preferably, the fill material is self- emulsifying upon contact with simulate gastric fluid.
  • Fill material comprises at least one solvent which is preferably suitable for dissolving the drug and/or any additional ingredients or excipients present therein.
  • solvent i. Glycols and glycol ethers
  • a preferred solvent is a glycol or glycol ether. Suitable glycol ethers include those conforming to formula (X):
  • Glycol ethers used as solvents in fill material typically have a molecular weight of about 75 to about 1000, preferably about 75 to about 500, and more preferably about 100 to about 300.
  • the glycol ethers used in fill material of this embodiment must be pharmaceutically acceptable and must meet all other conditions prescribed herein.
  • Non-limiting examples of glycol ethers that may be used in fill material of this embodiment include ethylene glycol monomethyl ether, ethylene glycol dimethyl ether, ethylene glycol monoethyl ether, ethylene glycol diethyl ether, ethylene glycol monobutyl ether, ethylene glycol dibutyl ether, ethylene glycol monophenyl ether, ethylene glycol monobenzyl ether, ethylene glycol butylphenyl ether, ethylene glycol terpinyl ether, diethylene glycol monomethyl ether, diethylene glycol dimethyl ether, diethylene glycol monoethyl ether, diethylene glycol diethyl ether, diethylene glycol divinyl ether, ethylene glycol monobutyl ether, diethylene glycol dibutyl ether, diethylene glycol monoisobutyl ether, triethylene glycol dimethyl ether, triethylene glycol monoethyl ether, triethylene glycol monobutyl ether, t
  • glycol ether solvent is diethylene glycol monoethyl ether, sometimes referred to in the art as DGME or ethoxydi glycol. It is available for example under the trademark TranscutolTM of Gattefosse Corporation.
  • Glycols suitable as solvents in fill material include propylene glycol, 1,3-butanediol and polyethylene glycols.
  • a presently preferred solvent is polyethylene glycol (PEG).
  • any pharmaceutically acceptable PEG can be used.
  • the PEG has an average molecular weight of about 100 to about 10,000, and more preferably about 100 to about 1,000. Still more preferably, the PEG is of liquid grade.
  • PEGs that can be used in solvent liquids of this invention include PEG-200, PEG-350, PEG-400, PEG-540 and PEG-600. See for example Flick (1998), op. cit., p. 392.
  • a presently preferred PEG has an average molecular weight of about 375 to about 450, as exemplified by PEG-400.
  • PEGs such as PEG-400 have many desirable properties as solvents for poorly water-soluble drugs.
  • the drug can be dissolved or solubilized at a very high concentration in PEG-400, enabling formulation of a therapeutically effective dose in a very small volume of solvent liquid. This is especially important where the resulting solution is to be encapsulated, as capsules of a size convenient for swallowing can be prepared containing a therapeutically effective dose even of a drug such as celecoxib having a relatively high dose requirement for efficacy.
  • ethanol, water, and other excipients identified as co-solvents hereinbelow or elsewhere can, if desired, be used as solvents in a fill material of the invention.
  • one or more solvents will be present in a fill material in a total amount of about 5% to about 95%, preferably about 10% to about 90% and more preferably about 15% to about 85% of the dosage form on a dry weight basis.
  • a fill material of this embodiment optionally comprises one or more pharmaceutically acceptable co-solvents.
  • suitable co-solvents include additional glycols, alcohols, for example ethanol and n-butanol; oleic and linoleic acid triglycerides, for example soybean oil; caprylic/capric triglycerides, for example MiglyolTM 812 of Huls; caprylic/capric mono- and diglycerides, for example CapmulTM MCM of Abitec; polyoxyethylene caprylic/capric glycerides such as polyoxyethylene (8) caprylic/capric mono- and diglycerides, for example LabrasolTM of Gattefosse; propylene glycol fatty acid esters, for example propylene glycol laurate; polyoxyethylene (35) castor oil, for example CremophorTM EL of BASF; polyoxyethylene glyceryl trioleate, for example TagatTM TO of Goldschmidt; lower alkyl
  • Any pharmaceutically acceptable gelatin capsules can be used to prepare a dosage form of the present invention, including hard and soft gelatin capsules. Such capsules can be prepared according to any suitable process. i. Hard gelatin capsules
  • Non-limiting methods for preparing hard gelatin capsules are described in the following patents and/or publications, each of which is hereby incorporated by reference herein.
  • capsule shells are soft gelatin capsule shells.
  • Such shells can be prepared according to any suitable process including but not limited to the plate process, vacuum process, or the rotary die process. See, for example, (1) Ansel et al. (1995) in Pharmaceutical Dosage Forms and Drug Delivery Systems, 6th ed., Williams
  • capsule shell and “gelatin capsule shell” embraces capsule half-shells (that can cooperate to form a whole capsule shell) and whole capsule shells (that define a fill volume). Such term also embraces soft gelatin capsule shells and hard gelatin capsules, irrespective of the process by which such shells are made.
  • sealed capsule shell means to denote a whole capsule shell that defines a fill volume, that such fill volume can contain a fill material, that such fill material is enclosed in the whole capsule shell, and that such enclosure affords the fill material more than a de minimus amount of protection from the atmosphere outside of the whole capsule shell.
  • Dosage forms of the invention are useful in treatment and prevention of a very wide range of disorders mediated by COX-2, including but not restricted to disorders characterized by inflammation, pain and/or fever. Such dosage forms are especially useful as anti-inflammatory agents, such as in treatment of arthritis, with the additional benefit of having significantly less harmful side effects than compositions of conventional NSAIDs that lack selectivity for COX-2 over COX-1. In particular, dosage forms of the invention have reduced potential for gastrointestinal toxicity and gastrointestinal irritation, including upper gastrointestinal ulceration and bleeding, by comparison with compositions of conventional NSAIDs.
  • dosage forms of the invention are particularly useful as an alternative to conventional NSAIDs where such NSAIDs are contraindicated, for example in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; gastrointestinal bleeding, coagulation disorders including anemia such as hypoprothrombinemia, hemophilia or other bleeding problems; kidney disease; or in patients prior to surgery or patients taking anticoagulants.
  • NSAIDs are contraindicated, for example in patients with peptic ulcers, gastritis, regional enteritis, ulcerative colitis, diverticulitis or with a recurrent history of gastrointestinal lesions; gastrointestinal bleeding, coagulation disorders including anemia such as hypoprothrombinemia, hemophilia or other bleeding problems; kidney disease; or in patients prior to surgery or patients taking anticoagulants.
  • Contemplated dosage forms are useful to treat a variety of arthritic disorders, including but not limited to rheumatoid arthritis, spondyloarthropathies, gouty arthritis, osteoarthritis, systemic lupus erythematosus and juvenile arthritis.
  • Such dosage forms are useful in treatment of asthma, bronchitis, menstrual cramps, preterm labor, tendonitis, bursitis, allergic neuritis, cytomegalovirus infection, apoptosis including HJN-induced apoptosis, lumbago, liver disease including hepatitis, skin-related conditions such as psoriasis, eczema, acne, burns, dermatitis and ultraviolet radiation damage including sunburn, and post-operative inflammation including that following ophthalmic surgery such as cataract surgery or refractive surgery.
  • Such dosage forms are useful to treat gastrointestinal conditions such as inflammatory bowel disease, Crohn's disease, gastritis, irritable bowel syndrome and ulcerative colitis.
  • Such dosage forms are useful in treating inflammation in such diseases as migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's syndrome, polymyositis, gingivitis, nephritis, hypersensitivity, swelling occurring after injury including brain edema, myocardial ischemia, and the like.
  • diseases as migraine headaches, periarteritis nodosa, thyroiditis, aplastic anemia, Hodgkin's disease, sclerodoma, rheumatic fever, type I diabetes, neuromuscular junction disease including myasthenia gravis, white matter disease including multiple sclerosis, sarcoidosis, nephrotic syndrome, Behcet's
  • Such dosage forms are useful in treatment of ophthalmic disorders, including without limitation inflammatory disorders such as endophthalmitis, episcleritis, retinitis, iriditis, cyclitis, choroiditis, keratitis, conjunctivitis and blepharitis, inflammatory disorders of more than one part of the eye, e.g., retinochoroiditis, iridocyclitis, iridocyclochoroiditis (also known as uveitis), keratoconjunctivitis, blepharoconjunctivitis, etc.; other COX-2 mediated retinopathies including diabetic retinopathy; ocular photophobia; acute trauma of any tissue of the eye including postsurgical trauma, e.g., following cataract or corneal transplant surgery; postsurgical ocular inflammation; intraoperative miosis; corneal graft rejection; ocular, for example retinal, neovascularization including that following injury or infection; ma
  • Such dosage forms are useful for treatment of certain central nervous system disorders, such as cortical dementias including Alzheimer's disease, neurodegeneration, and central nervous system damage resulting from stroke, ischemia and trauma.
  • treatment in the present context includes partial or total inhibition of dementias, including Alzheimer's disease, vascular dementia, multi-infarct dementia, pre-senile dementia, alcoholic dementia and senile dementia.
  • Such dosage forms are useful in treatment of allergic rhinitis, respiratory distress syndrome, endotoxin shock syndrome and liver disease.
  • Such dosage forms are useful in treatment of pain, including but not limited to postoperative pain, dental pain, muscular pain, and pain resulting from cancer.
  • dosage forms are useful for relief of pain, fever and inflammation in a variety of conditions including rheumatic fever, influenza and other viral infections including common cold, low back and neck pain, dysmenorrhea, headache, toothache, sprains and strains, myositis, neuralgia, synovitis, arthritis, including rheumatoid arthritis, degenerative joint diseases (osteoarthritis), gout and ankylosing spondylitis, bursitis, burns, and trauma following surgical and dental procedures.
  • Such dosage forms are useful for treating and preventing inflammation-related cardiovascular disorders, including vascular diseases, coronary artery disease, aneurysm, vascular rejection, arteriosclerosis, atherosclerosis including cardiac transplant atherosclerosis, myocardial infarction, embolism, stroke, thrombosis including venous thrombosis, angina including unstable angina, coronary plaque inflammation, bacterial-induced inflammation including Chlamydia-induced inflammation, viral induced inflammation, and inflammation associated with surgical procedures such as vascular grafting including coronary artery bypass surgery, revascula ⁇ zation procedures including angioplasty, stent placement, endarterectomy, or other invasive procedures involving arteries, veins and capillaries.
  • vascular diseases including coronary artery disease, aneurysm, vascular rejection, arteriosclerosis, atherosclerosis including cardiac transplant atherosclerosis, myocardial infarction, embolism, stroke, thrombosis including venous thrombosis, angina including unstable angina,
  • Such dosage forms are useful in treatment of angiogenesis-related disorders in a subject, for example to inhibit tumor angiogenesis.
  • Such dosage forms are useful in treatment of neoplasm, including metastasis; ophthalmological conditions such as corneal graft rejection, ocular neovascularization, retinal neovascularization including neovascularization following injury or infection, diabetic retinopathy, macular degeneration, retrolental fibroplasia and neovascular glaucoma; ulcerative diseases such as gast ⁇ c ulcer, pathological, but non-malignant, conditions such as hemangiomas, including infantile hemaginomas, angiofibroma of the nasopharynx and avascular necrosis of bone, and disorders of the female reproductive system such as endomet ⁇ osis.
  • Such dosage forms are useful in prevention and treatment of benign and malignant tumors and neoplasm including cancer, such as colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasm (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer, bladder cancer, pancreas cancer, ovary cancer, cervical cancer, lung cancer, breast cancer, skin cancer such as squamous cell and basal cell cancers, prostate cancer, renal cell carcinoma, and other known cancers that effect epithelial cells throughout the body.
  • cancer such as colorectal cancer, brain cancer, bone cancer, epithelial cell-derived neoplasm (epithelial carcinoma) such as basal cell carcinoma, adenocarcinoma, gastrointestinal cancer such as lip cancer, mouth cancer, esophageal cancer, small bowel cancer, stomach cancer, colon cancer, liver cancer
  • Neoplasms for which dosage forms of the invention are contemplated to be particularly useful are gastrointestinal cancer, Barrett's esophagus, liver cancer, bladder cancer, pancreatic cancer, ovarian cancer, prostate cancer, cervical cancer, lung cancer, breast cancer and skin cancer.
  • dosage forms can also be used to treat fibrosis that occurs with radiation therapy.
  • Such dosage forms can be used to treat subjects having adenomatous polyps, including those with familial adenomatous polyposis (FAP). Additionally, such dosage forms can be used to prevent polyps from forming in subjects at risk of FAP.
  • FAP familial adenomatous polyposis
  • Such dosage forms inhibit prostanoid-induced smooth muscle contraction by inhibiting synthesis of contractile prostanoids and hence can be of use in treatment of dysmenorrhea, premature labor, asthma and eosinophil-related disorders. They also can be of use for decreasing bone loss particularly in postmenopausal women (i.e., treatment of osteoporosis), and for treatment of glaucoma.
  • Preferred uses for dosage forms of the invention are for treatment of rheumatoid arthritis and osteoarthritis, for pain management generally (particularly post- oral surgery pain, post-general surgery pain, post-orthopedic surgery pain, and acute flares of osteoarthritis), for treatment of Alzheimer's disease, and for colon cancer chemoprevention.
  • dosage forms of the invention are useful for veterinary treatment of companion animals, exotic animals, farm animals, and the like, particularly mammals. More particularly, dosage forms of the invention are useful for treatment of COX-2 mediated disorders in horses, dogs and cats.
  • capsules containing fill formulation FI (comprising Sodium metabisulfite in an amount of about 3% by weight of the fill material) exhibited no pellicle formation during storage for a period of six months.
  • capsules containing fill formulation F2 (no sulfite compound) exhibited pellicle formation by two weeks of storage.
  • test material comprising PEG 400 and 414 ⁇ g/ml formaldehyde was prepared. Five aliquots, Al - A4, of the test material were drawn and placed in separate vials. Individually, one of glycine, sodium metabisulfite, sodium bisulfite, or no additional component, was added to each vial in an amount of 5 mg/ml, as shown in Table 3, to form test samples Al - A4, respectively.
  • test samples were stored at room temperature for a period of three days. After three days of storage, formaldehyde concentration in each sample was measured using HPLC. Amount of formaldehyde present in each sample (% weight of original amount) is shown in Table 4.
  • Tier I and Tier II results are very similar for this 6 month sample indicating that the change in drug release profile is not attributable to cross-linking. [0101] These data indicate that there was severe cross-linking observed in the Formulation 30. The change in the Tier U drug release profile (i.e. reduced delay) indicates that Tier I delayed release is the result of cross-linking for this formulation and further indicates that a significant delay in the drug release profile in humans would be likely.
  • the Formulation 19, containing sodium metabisulfite exhibits no measurable gelatin cross-linking through 6 months at stringent (40°C / 75% RH) storage conditions. These data demonstrate that the addition of sodium metabisulfite to this formulation significantly reduces the rate of cross-linking and indeed may inhibit cross-linking completely.
  • sodium metabisulfite is believed to inhibit cross-linking by a process in which sodium metabisulfite reacts with aldehydes forming a bisulfite addition product.
  • sodium metabisulfite may effectively scavenges aldehydes making them unavailable to promote cross-linking in the gelatin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)

Abstract

L'invention a pour objet une forme posologique pharmaceutique comprenant une capsule de gélatine contenant une charge ; ladite charge comprend : (a) un médicament inhibiteur de COX-2 sélectif, peu soluble dans l'eau, et (b) un composé de sulfite présent en une quantité suffisante pour inhiber la réticulation de la gélatine dans ladite capsule de gélatine, lors du stockage de la forme posologique, pour une durée de 6 mois, dans un récipient fermé, maintenu à 40 °C et comprenant 75 % d'humidité relative.
PCT/US2003/024044 2002-07-31 2003-07-31 Forme posologique pharmaceutique comprenant un compose de sulfite Ceased WO2004022032A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0313064-9A BR0313064A (pt) 2002-07-31 2003-07-31 Forma de dosagem farmacêutica compreendendo um composto de sulfito
CA002493974A CA2493974A1 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique comprenant un compose de sulfite
MXPA05001272A MXPA05001272A (es) 2002-07-31 2003-07-31 Forma de dosificiacion farmaceutica que comprende un compuesto de sulfito.
AU2003257102A AU2003257102A1 (en) 2002-07-31 2003-07-31 Pharmaceutical dosage form comprising a sulfite compound
JP2004534259A JP2006500389A (ja) 2002-07-31 2003-07-31 亜硫酸塩化合物を含有する医薬剤形
EP03794452A EP1526847A2 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique comprenant un compose de sulfite

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US39977602P 2002-07-31 2002-07-31
US39986202P 2002-07-31 2002-07-31
US39980802P 2002-07-31 2002-07-31
US39986302P 2002-07-31 2002-07-31
US60/399,862 2002-07-31
US60/399,863 2002-07-31
US60/399,808 2002-07-31
US60/399,776 2002-07-31

Publications (2)

Publication Number Publication Date
WO2004022032A2 true WO2004022032A2 (fr) 2004-03-18
WO2004022032A3 WO2004022032A3 (fr) 2004-08-12

Family

ID=31192378

Family Applications (4)

Application Number Title Priority Date Filing Date
PCT/US2003/024045 Ceased WO2004010974A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine a reticulation reduite
PCT/US2003/024042 Ceased WO2004010972A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine resistant aux pellicules
PCT/US2003/024044 Ceased WO2004022032A2 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique comprenant un compose de sulfite
PCT/US2003/024043 Ceased WO2004010973A2 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique conservant un profil de dissolution stable au stockage

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/US2003/024045 Ceased WO2004010974A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine a reticulation reduite
PCT/US2003/024042 Ceased WO2004010972A2 (fr) 2002-07-31 2003-07-31 Capsule de gelatine resistant aux pellicules

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2003/024043 Ceased WO2004010973A2 (fr) 2002-07-31 2003-07-31 Forme posologique pharmaceutique conservant un profil de dissolution stable au stockage

Country Status (7)

Country Link
EP (4) EP1526844A2 (fr)
JP (4) JP2005538994A (fr)
AU (4) AU2003257982A1 (fr)
BR (4) BR0313149A (fr)
CA (4) CA2494069A1 (fr)
MX (4) MXPA05001166A (fr)
WO (4) WO2004010974A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7884094B2 (en) 2005-02-17 2011-02-08 Synta Pharmaceuticals Corp. Compounds for the treatment of proliferative disorders
US8895059B2 (en) 2002-06-05 2014-11-25 Ivax Pharmaceuticals S.R.O. Reduction of cross-linking gelatin in gelatin capsules

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
CA2616508C (fr) * 2005-07-26 2015-02-24 Nicox S.A. Preparation pharmaceutique de derives nitrooxy d'ains
JP5503939B2 (ja) * 2009-10-16 2014-05-28 東洋カプセル株式会社 アゼラスチン塩酸塩含有カプセル剤
JP6887456B2 (ja) 2018-07-04 2021-06-16 キャプシュゲル・ベルジウム・エヌ・ヴィ 白色化剤として界面活性剤又は界面活性剤と塩を含有する皮膜形成性組成物
US11364478B2 (en) * 2019-05-22 2022-06-21 Mezzimatic, LLC Method of manufacturing throwable paintballs and paintballs made therefrom
AU2021390901B9 (en) * 2020-12-01 2024-11-21 Lg Chem, Ltd. Stable oral formulation containing 1-(3-cyano-1-isopropyl-indol-5-yl)pyrazole-4-carboxylic acid
CN113230241A (zh) * 2021-06-11 2021-08-10 北京畅盛医药科技有限公司 三羟甲基氨基甲烷盐在治疗心脑血管病的药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115094B2 (fr) * 1972-11-01 1976-05-14
US4349529A (en) * 1980-04-14 1982-09-14 E. R. Squibb & Sons, Inc. Diagnostic and therapeutic capsules and method of producing
US4590183A (en) * 1985-04-22 1986-05-20 Sterling Drug Inc. Gastric cytoprotection with sodium thiosulfate in oral administration of aspirin
FR2617047B1 (fr) * 1987-06-23 1991-05-10 Sanofi Sa Composition de gelatine resistant au tannage, capsules a base de cette composition et leur application pharmaceutique, notamment au fenofibrate
JP2790659B2 (ja) * 1989-06-30 1998-08-27 帝国臓器製薬株式会社 ゼラチンカプセル剤
KR100338851B1 (ko) * 1994-03-15 2002-10-12 센주 세이야꾸 가부시키가이샤 프라노프로펜의안정화방법및안정한프라노프로펜약제
IT1269583B (it) * 1994-04-26 1997-04-08 Bayer Italia Spa Preparazioni farmaceutiche a base di una soluzione di ketoprofene in capsule di gelatina molle e metodo per la loro produzione
DK0695544T3 (da) * 1994-08-05 2001-01-02 Shionogi & Co Hårde gelatinekapsler, der kan modstå denaturering, og fremgangsmåde til fremstilling heraf
US5620704A (en) * 1994-11-07 1997-04-15 Warner-Lambert Company Process for stabilizing gelatin products
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895059B2 (en) 2002-06-05 2014-11-25 Ivax Pharmaceuticals S.R.O. Reduction of cross-linking gelatin in gelatin capsules
US7884094B2 (en) 2005-02-17 2011-02-08 Synta Pharmaceuticals Corp. Compounds for the treatment of proliferative disorders
US8269017B2 (en) 2005-02-17 2012-09-18 Synta Pharmaceuticals Corporation Compounds for the treatment of proliferative disorders
US8598366B2 (en) 2005-02-17 2013-12-03 Synta Pharmaceuticals Corporation Compounds for the treatment of proliferative disorders
US9090603B2 (en) 2005-02-17 2015-07-28 Synta Pharmaceuticals Corporation Compounds for the treatment of proliferative disorders

Also Published As

Publication number Publication date
BR0312875A (pt) 2005-06-28
EP1526844A2 (fr) 2005-05-04
AU2003257102A8 (en) 2004-03-29
EP1526847A2 (fr) 2005-05-04
CA2494069A1 (fr) 2004-02-05
MXPA05001167A (es) 2005-05-16
WO2004010974A2 (fr) 2004-02-05
CA2493980A1 (fr) 2004-02-05
BR0313150A (pt) 2005-06-28
AU2003257981A8 (en) 2004-02-16
CA2494358A1 (fr) 2004-02-05
CA2493974A1 (fr) 2004-03-18
AU2003257102A1 (en) 2004-03-29
WO2004010973A3 (fr) 2004-08-05
MXPA05001272A (es) 2005-04-28
WO2004010973A2 (fr) 2004-02-05
MXPA05001166A (es) 2005-05-16
WO2004010972A3 (fr) 2004-07-29
AU2003257982A1 (en) 2004-02-16
EP1526845A2 (fr) 2005-05-04
BR0313149A (pt) 2005-06-28
WO2004022032A3 (fr) 2004-08-12
AU2003257982A8 (en) 2004-02-16
AU2003257103A1 (en) 2004-02-16
WO2004010974A3 (fr) 2004-08-05
EP1526846A2 (fr) 2005-05-04
JP2005538102A (ja) 2005-12-15
JP2005538994A (ja) 2005-12-22
AU2003257981A1 (en) 2004-02-16
MXPA05000862A (es) 2005-04-19
JP2006500389A (ja) 2006-01-05
WO2004010972A2 (fr) 2004-02-05
BR0313064A (pt) 2005-06-28
AU2003257103A8 (en) 2004-02-16
JP2005538993A (ja) 2005-12-22

Similar Documents

Publication Publication Date Title
RU2299061C2 (ru) Способ получения самостоятельно мелко эмульгирующейся фармацевтической композиции
US20040131670A1 (en) Pellicle-resistant gelatin capsule
KR20040012761A (ko) 안정화된 경구 약학적 조성물
KR20040018355A (ko) 낮은 수용해도 약물(ｃｏｘ-2 저해제), 용매, 지방산 및유기아민을 포함하는 경구 송달가능한 약학적 조성물
AU2002254609A1 (en) Orally deliverable pharmaceutical composition comprising an active compound having an aminosulfonyl group (COX-2 inhibitor), a polyethylene glycol and a free-radical scavenging antioxidant
AU2002305175A1 (en) Orally deliverable pharmaceutical composition comprising a drug of low water solubility (COX-2 inhibitor), a solvent, a fatty acid and an organic amine
EP1526847A2 (fr) Forme posologique pharmaceutique comprenant un compose de sulfite
US20040105884A1 (en) Pharmaceutical dosage form comprising a sulfite compound
US20040105883A1 (en) Pharmaceutical dosage form capable of maintaining stable dissolution profile upon storage
US20030143271A1 (en) Drug mixture with enhanced dissolution rate
US20040105885A1 (en) Gelatin capsule exhibiting reduced cross-linking

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2493974

Country of ref document: CA

Ref document number: 2003794452

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: PA/a/2005/001272

Country of ref document: MX

Ref document number: 2004534259

Country of ref document: JP

WWP Wipo information: published in national office

Ref document number: 2003794452

Country of ref document: EP